CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

被引：12

作者：

Moskowitz, Craig H. ^{[1
]}

Younes, Anas ^{[2
]}

de Vos, Sven ^{[3
]}

Bociek, R. Gregory ^{[4
]}

Gordon, Leo I. ^{[5
]}

Witzig, Thomas E. ^{[6
]}

Gascoyne, Randy D. ^{[7
]}

West, Brian ^{[8
]}

Nolop, Keith ^{[8
]}

Steidl, Christian

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[4] Univ Nebraska Med Ctr, Sect Oncol & Hematol, Omaha, NE USA

[5] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA

[6] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA

[7] BC Canc Agcy, Ctr Lymphoid Canc, Dept Pathol, Vancouver, BC, Canada

[8] Plexxikon Inc, Berkeley, CA USA

来源：

关键词：

D O I：

10.1182/blood.V120.21.1638.1638

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1638

引用

页数：2